ReviewExpert review of vaccines2016
Questions regarding the safety and duration of immunity following live yellow fever vaccination.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.Frontiers in immunology · 2019Trial
- Drought dynamics explain once in a century yellow fever virus outbreak in Brazil with implications for climate change.Science advances · 2026Article
- Yellow fever in older adults: an overlooked high-risk population in South American outbreaks.Sustainable microbiology · 2026Article
- Lessons learned from successful implementation of tetanus and diphtheria vaccination programs.Clinical microbiology reviews · 2025Review
- A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers.Vaccines · 2025Article
- From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.Vaccines · 2025Review
- Epidemic Outbreaks Related to Yellow Fever Viruses.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Tetanus Vaccination in Agricultural Workers: A Retrospective Study on Seroprevalence over 10 Years.Vaccines · 2024Article
- Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell reports. Medicine · 2024Article
- Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches.Le infezioni in medicina · 2024Review
- Reply to Martin and Dauby.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.Science translational medicine · 2023Article
- Zoonoses and gold mining: A cross-sectional study to assess yellow fever immunization, Q fever, leptospirosis and leishmaniasis among the population working on illegal mining camps in French Guiana.PLoS neglected tropical diseases · 2022Article
- Review
- Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort.Frontiers in immunology · 2022Article
- Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.The Journal of infectious diseases · 2020Article
- Long-Term Protection of Rhesus Macaques from Zika Virus Reinfection.Journal of virology · 2020Article
- Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.